The price of Ginkgo Bioworks Holdings Inc (NYSE: DNA) closed at $1.01 in the last session, down -3.81% from day before closing price of $1.05. On the day, 14046314 shares were traded.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Ratios:
We take a closer look at DNA’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 6.11 and its Current Ratio is at 6.11. In the meantime, Its Debt-to-Equity ratio is 0.22 whereas as Long-Term Debt/Eq ratio is at 0.20.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Raymond James on November 14, 2023, Downgraded its rating to Mkt Perform and sets its target price to $2.50 from $3.50 previously.
Goldman Downgraded its Neutral to Sell on June 02, 2023, whereas the target price for the stock was revised from $3 to $1.25.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Apr 02 ’24 when Dmytruk Mark E. sold 51,169 shares for $1.05 per share. The transaction valued at 53,727 led to the insider holds 865,079 shares of the business.
Dmytruk Mark E. sold 38,826 shares of DNA for $48,765 on Mar 04 ’24. The insider now owns 808,125 shares after completing the transaction at $1.26 per share. On Feb 02 ’24, another insider, Dmytruk Mark E., who serves as the insider of the company, sold 39,569 shares for $1.21 each. As a result, the insider received 47,799 and left with 761,737 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.16 while its Price-to-Book (P/B) ratio in mrq is 1.73.
Stock Price History:
Over the past 52 weeks, DNA has reached a high of $2.55, while it has fallen to a 52-week low of $0.99.
Shares Statistics:
A total of 1.53B shares are outstanding, with a floating share count of 1.35B. Insiders hold about 33.65% of the company’s shares, while institutions hold 58.66% stake in the company.
Earnings Estimates
The company has Strategic CRISPR & Gene Editing analysts who recommend its stock at the moment. The consensus estimate for the next quarter is $1.01, with high estimates of $379.87 and low estimates of $35.80.
EPS for the following year is $Stocks, with Stocks analysts recommending between $ETF and $ETF.
